Melanotan 2 UK: Research-Grade MT-2 with Full COAs (2026)

Melanotan 2 UK: Research-Grade Supply, Melanocortin Receptor Science, and Sourcing Intelligence

In a 1998 double-blind trial published in Urology (PMID: 9869628), Wessells and colleagues demonstrated that melanotan 2 (MT-2) produced erections in 80% of men with organic erectile dysfunction at a 0.025 mg/kg dose—an effect mediated entirely through melanocortin-4 receptors (MC4R) in the central nervous system. Separately, a 1996 phase-I safety study by Dorr et al. (PMID: 8801281) confirmed dose-dependent skin pigmentation via melanocortin-1 receptors (MC1R) in dermal melanocytes. These are two distinct receptor pathways with unrelated physiological outcomes, yet most commercial content discussing melanotan 2 UK supply conflates them or ignores the mechanistic separation entirely.

This creates a knowledge gap that UK-based researchers and informed consumers can exploit when evaluating suppliers. Understanding which melanocortin receptor subtypes mediate which effects—and how to interpret third-party certificates of analysis (COAs) that verify peptide identity and purity—is the difference between research-grade material and underdosed or contaminated product.

Arma Peptides supplies Melanotan 2 10mg UK with ≥99% HPLC-verified purity, batch-specific COAs published per order, and direct UK delivery. This article deconstructs the melanocortin receptor pharmacology, reviews the clinical evidence base, and provides a UK-specific sourcing framework grounded in analytical chemistry rather than marketing copy.

Melanocortin Receptor Pharmacology: Why MT-2 Isn’t Just “the Tanning Peptide”

Melanotan 2 is a synthetic heptapeptide analogue of alpha-melanocyte stimulating hormone (α-MSH), designed for increased potency and duration of action. Its molecular formula is C₅₀H₆₉N₁₅O₉, with a molecular weight of 1,024.18 Da. The cyclised structure—formed by a disulfide bridge between cysteine residues at positions 4 and 10—confers resistance to proteolytic degradation, extending half-life compared to endogenous α-MSH.

MT-2 binds as an agonist to four of the five melanocortin receptor subtypes:

• MC1R (melanocortin-1 receptor): Expressed predominantly in dermal melanocytes. Activation stimulates eumelanin synthesis via upregulation of tyrosinase and TRP-1 (tyrosinase-related protein 1), increasing melanin content independent of UV exposure. This is the pathway responsible for pigmentation effects.
• MC3R: Expressed in hypothalamus and limbic structures; role in energy homeostasis and inflammatory modulation. Clinical relevance for MT-2 unclear.
• MC4R (melanocortin-4 receptor): Expressed in paraventricular nucleus, spinal autonomic nuclei, and cortical regions. Mediates erectile response via downstream nitric oxide signalling in the corpus cavernosum. Also implicated in appetite suppression and energy expenditure.
• MC5R: Expressed in exocrine glands. Limited data on functional contribution to MT-2 effects.

The critical insight: MC1R and MC4R activation are mechanistically and anatomically independent. A researcher or end-user experiencing pigmentation (MC1R) does not predict magnitude of MC4R-mediated effects, and vice versa. Receptor expression density, competitive endogenous ligand tone, and pharmacokinetic variables differ between skin and CNS compartments.

This is not theoretical. In the Wessells et al. trial (PMID: 9869628), participants exhibited erectile responses within 2–6 hours post-administration, while pigmentation effects (when they occurred) developed over days to weeks. The timescales alone confirm distinct pathways. King et al. (2007, PMID: 17185243) reviewed the melanocortin system’s role in penile erection and noted that MC4R knockout mice show complete abolition of MT-2-induced erections, while MC1R knockout has no effect on erectile function.

For UK researchers sourcing material, this means COAs must confirm the correct peptide sequence and disulfide bond integrity. A linear (non-cyclised) peptide may still bind MC1R with some affinity, but MC4R binding requires the constrained conformation. HPLC alone does not confirm cyclisation—mass spectrometry (MS) or amino acid analysis is required for full structural verification.

Clinical Evidence: What Published Trials Show (and Don’t Show)

The earliest human trial of melanotan 2 was conducted by Dorr et al. in 1996 (PMID: 8801281), a phase-I dose-escalation study in 24 healthy male volunteers. Doses ranged from 0.01 mg/kg to 0.16 mg/kg subcutaneously. Results:

• Dose-dependent skin darkening observed at all doses above 0.04 mg/kg, with maximal response at 0.16 mg/kg.
• Onset: visible pigmentation within 48 hours; peak at 7–10 days.
• Adverse effects: nausea (dose-dependent, occurring in 67% at highest dose), flushing, spontaneous erections (reported by 8/24 participants without sexual stimulation).
• No serious adverse events; transient elevations in blood pressure (mean +8 mmHg systolic) noted at higher doses.

The spontaneous erections were unexpected and led directly to the Wessells trial two years later. In that 1998 double-blind crossover study (PMID: 9869628), 20 men with organic erectile dysfunction (post-prostatectomy or diabetes-related) received MT-2 at 0.025 mg/kg subcutaneously. Outcomes:

• 80% achieved erections sufficient for intercourse within 6 hours.
• Effect was consistent across subgroups (diabetic and post-surgical).
• Mechanism confirmed via melanocortin receptor antagonism studies in rodent models (same publication).
• Side effects: mild nausea (30%), flushing (20%), no cardiovascular events.

Critically, these trials used pharmaceutical-grade synthetic MT-2 with confirmed identity and purity. The 0.025 mg/kg dose in Wessells et al. translates to approximately 1.75–2 mg for an 80 kg individual. This is the only human dose with published efficacy data for erectile function. Many UK users report using higher doses (5–10 mg loading doses for pigmentation), but no published human data supports these protocols, and adverse event frequency increases dose-dependently.

Notably absent from the literature: long-term safety data. The longest published human trial duration is 28 days. Effects on melanocyte proliferation, potential for dysplastic changes, cardiovascular outcomes beyond acute blood pressure, and neuroendocrine feedback over months or years remain unknown. This is not to discourage research use, but to contextualise the evidence base accurately.

UK Sourcing Intelligence: How to Evaluate Melanotan 2 Suppliers

The UK peptide supply market includes pharmaceutical wholesalers, compounding labs, grey-market importers, and research chemical vendors. Quality variance is extreme. The following framework applies specifically to UK-based sourcing:

1. Purity Verification via HPLC

High-performance liquid chromatography (HPLC) separates peptide content from impurities (truncated sequences, deletion analogues, acetate or TFA salts). A legitimate COA will report:

• Purity by area-under-curve (AUC): ≥98% is acceptable for research; ≥99% is optimal. Anything below 95% suggests poor synthesis or degradation.
• Chromatogram: The visual trace should show a single dominant peak with minimal satellite peaks. Multiple large peaks indicate mixture or contamination.
• Column and method details: Reverse-phase C18 column with gradient elution (e.g., acetonitrile/water with 0.1% TFA) is standard. If method isn’t specified, the COA is not auditable.

Arma Peptides publishes HPLC COAs for every batch of Melanotan 2 10mg UK, with chromatograms and method parameters included. Batch numbers on vial labels correspond to COA batch numbers, enabling traceability.

2. Mass Spectrometry (MS) for Identity Confirmation

HPLC confirms purity but not identity. A 7-amino-acid deletion analogue of MT-2 might co-elute or appear as a single HPLC peak but would have a different molecular weight. Mass spectrometry (ESI-MS or MALDI-TOF) provides the molecular weight to ±1 Da precision, confirming the peptide is actually MT-2 (expected: 1024.18 Da for the free peptide, or higher if salt form).

COAs should report observed m/z and theoretical m/z. A discrepancy >2 Da suggests incorrect sequence or incomplete cyclisation. If MS data is absent, ask the supplier directly. If they cannot provide it, assume they have not verified identity.

3. UK Regulatory Context

Under UK law (Medicines and Healthcare products Regulatory Agency guidelines), melanotan 2 is not a licensed medicine. It is legal to purchase and possess for research purposes, but it is illegal to supply with the intention of human consumption. Reputable UK suppliers, including Arma Peptides, label material “for research use only” and do not provide dosing instructions for human use.

This is not a legal loophole; it reflects the genuine status of MT-2 as an investigational compound. Buyers should be aware that product liability and quality assurance are self-regulated in the research chemical sector. There is no Medicines and Healthcare products Regulatory Agency (MHRA) pre-market approval or GMP requirement. This is why third-party COAs are non-negotiable.

4. Presentation and Storage

MT-2 should be supplied as a lyophilised (freeze-dried) powder in a sterile vial, ideally under inert atmosphere (argon or nitrogen) to prevent oxidation of the disulfide bond. Avoid suppliers offering pre-reconstituted solutions unless clearly labelled with a short expiry date—peptides in aqueous solution degrade rapidly, especially at non-frozen temperatures.

Upon receipt, store at -20°C or colder. Once reconstituted (typically in bacteriostatic water or sterile saline), use within 30 days if refrigerated at 4°C. Freeze-thaw cycles degrade peptide integrity—aliquot into single-use vials if repeated freeze is unavoidable.

5. Price as a Quality Signal

Synthesis of a 7-mer cyclic peptide with disulfide bond formation is not trivial. Legitimate synthesis costs (solid-phase peptide synthesis, cleavage, purification, lyophilisation, COA testing) are non-negligible. In the UK market, 10 mg of ≥99% MT-2 typically retails between £35–£60. Prices significantly below this range (e.g., £15–£20 per 10 mg) often correlate with under-dosing (vial contains 5 mg instead of 10 mg), low purity (<90%), or absence of COAs.

Arma Peptides Shop pricing reflects HPLC-verified material and transparent sourcing. Higher cost is not always better, but dramatically low cost is nearly always a red flag.

Research Protocols: Dosing Data from Published Literature

The following is provided as reference to published human trials and is not medical advice. All use of melanotan 2 outside of registered clinical trials is at the user’s own risk and should be conducted under appropriate oversight.

Erectile Function (MC4R-Mediated)

Wessells et al. (PMID: 9869628) used 0.025 mg/kg subcutaneously, administered 2–6 hours prior to intended effect. For an 80 kg individual, this is approximately 2 mg. This is the only human dose with published efficacy and safety data for erectile outcomes.

Pigmentation (MC1R-Mediated)

Dorr et al. (PMID: 8801281) observed dose-dependent tanning at 0.04–0.16 mg/kg, with maximal response at the upper dose. For an 80 kg individual, this translates to 3.2–12.8 mg. Pigmentation was cumulative over repeated doses (daily for 7 days in the trial). Anecdotal UK research protocols often cite “loading phases” of 0.5–1 mg daily until desired pigmentation is achieved, followed by maintenance doses of 0.5 mg weekly, but these are not validated in controlled trials.

Considerations

• Onset: MC4R effects (erectile, appetite suppression) occur within hours; MC1R effects (pigmentation) require days to weeks.
• Nausea: Most common adverse effect, dose-dependent. Occurs in ~30% at 2 mg, ~67% at higher doses. Can be mitigated by dose fractionation or antiemetic co-administration (in research contexts).
• Flushing: Transient, usually resolves within 1–2 hours.
• Spontaneous erections: Reported in ~30% of male users, can occur without sexual stimulation due to central MC4R activation.

Researchers interested in isolating MC4R effects without pigmentation may consider PT-141 10mg UK (bremelanotide), a structurally related peptide with higher MC4R selectivity and minimal MC1R activity. PT-141 was developed specifically to separate sexual effects from pigmentation and has FDA approval (in the US) for hypoactive sexual desire disorder in premenopausal women.

Melanotan 2 Variants: Acetate, Nasal Spray, and Formulation Differences

Several formulations of melanotan 2 are available in the UK market. Understanding the differences is essential for selecting appropriate material.

Melanotan 2 Standard vs. Acetate Salt

The peptide can be supplied as the free base or as an acetate salt (or TFA salt, less common). Melanotan 2 Acetate 10mg refers to the acetate salt form. Key differences:

• Molecular weight: Acetate salt form is slightly heavier due to the acetate counterion (~60 Da per acetate group). This means a 10 mg vial of acetate salt contains slightly less MT-2 peptide by molar amount than 10 mg of free base—approximately 5–8% less, depending on the number of acetate groups.
• Solubility: Acetate salts are generally more water-soluble, reconstituting more readily in bacteriostatic water.
• Stability: No significant difference in lyophilised form; both are stable at -20°C for years.

From a research perspective, either form is acceptable as long as the COA specifies which form is present and the purity is calculated correctly. Arma Peptides supplies both standard and acetate forms with full analytical documentation.

Nasal Spray Formulation

Melanotan 2 Nasal Spray 10mg is a pre-formulated solution designed for intranasal administration. This delivery route bypasses first-pass metabolism and offers faster absorption compared to subcutaneous injection, with onset in 15–30 minutes for MC4R effects.

However, bioavailability via nasal mucosa is lower than subcutaneous—estimated at 20–40% based on pharmacokinetic modelling (no published human PK study exists for intranasal MT-2). This means a 1 mg intranasal dose may be equivalent to 0.2–0.4 mg subcutaneous. Dosing adjustments are necessary, and onset/duration curves differ.

Nasal formulations must include preservatives (benzyl alcohol or similar) and buffering agents to maintain pH 5.5–6.5 for mucosal compatibility. Users with nasal sensitivity or chronic rhinitis may experience reduced absorption. COAs for nasal spray should include sterility testing and endotoxin limits in addition to peptide purity.

Comparing MT-2 to Related Melanocortin Agonists

For UK researchers focused exclusively on sexual function without pigmentation, PT-141 10mg UK offers a superior side-effect profile. For those seeking both effects or using pigmentation as a biomarker of receptor engagement, Melanotan 2 10mg UK remains the most studied option.

UK Delivery, Packaging, and Handling

Arma Peptides ships from UK-based warehouses with next-day delivery options available domestically. All peptides are shipped in insulated packaging with ice packs to maintain cold chain integrity, essential for preserving lyophilised peptide stability during transit.

Upon arrival, inspect the vial seal and vacuum. A properly lyophilised vial will have a visible “cake” or powder adhered to the vial wall, and a slight vacuum when the cap is removed (indicated by a hissing sound or resistance when inserting a needle through the stopper). Absence of vacuum or presence of liquid suggests compromised seal or improper lyophilisation.

Transfer immediately to -20°C storage. Do not store in a frost-free freezer (temperature cycling degrades peptides). If immediate freezing is not possible, refrigeration at 4°C is acceptable for up to 7 days, but long-term room temperature storage will cause significant degradation.

Frequently Asked Questions

1. What is the difference between Melanotan 1 and Melanotan 2 in terms of UK availability?

Melanotan 1 (afamelanotide) is a linear peptide with high MC1R selectivity, developed for photoprotection in patients with erythropoietic protoporphyria. It has regulatory approval in the EU (under brand name Scenesse) as an implant formulation administered by specialists. It is not widely available in the UK research chemical market. Melanotan 2 is a cyclic analogue with broader receptor activity (MC1R and MC4R) and is available from research suppliers like Arma Peptides. MT-2 is more potent and has a longer half-life due to its cyclic structure and resistance to enzymatic degradation. For pigmentation with minimal MC4R activity, MT-1 is superior; for combined pigmentation and MC4R effects, MT-2 is the only viable option in the UK research context.

2. How do I verify that a melanotan 2 supplier’s COA is legitimate?

Legitimate COAs include: (1) batch number matching the vial label, (2) third-party lab name and contact information (not “in-house testing”), (3) chromatogram or spectrum image, (4) method details (HPLC column, mobile phase, MS ionisation method), and (5) date of analysis within the last 6–12 months. Red flags include: generic COAs with no batch number, impossibly perfect results (e.g., 100.0% purity), absence of testing lab identification, or refusal by the supplier to provide COAs before purchase. Arma Peptides provides COAs on request prior to purchase and includes them with every order. Cross-check the lab name online—legitimate analytical labs have web presence and accreditation (ISO 17025 or equivalent).

3. Can melanotan 2 cause permanent pigmentation changes?

MT-2 stimulates melanin synthesis, not melanocyte proliferation (at physiological concentrations). Pigmentation increases while MT-2 is present and binding to MC1R, and fades over weeks to months after cessation, as melanin is naturally shed with keratinocyte turnover (skin cell renewal cycle is ~28 days). There is no evidence from published human trials (up to 28 days duration) of permanent pigmentation. However, there is theoretical concern (based on rodent studies, not human data) that chronic high-dose MC1R stimulation could increase melanocyte activity or nevi (mole) growth. No long-term human data exists. Individuals with atypical mole syndrome, family history of melanoma, or extensive sun damage should exercise additional caution. Annual dermatological examination is advisable for chronic users.

4. Why does melanotan 2 cause nausea, and can it be avoided?

Nausea is mediated by MC4R activation in the area postrema (brainstem vomiting center) and possibly by MC3R in hypothalamic regions. It is dose-dependent and occurs more frequently at doses >0.05 mg/kg. Strategies to reduce nausea include: (1) dose fractionation (split a 2 mg dose into 0.5 mg every 2 hours), (2) administering with food, (3) gradual dose escalation (start at 0.25 mg and increase by 0.25 mg every 3 days), and (4) co-administration of antiemetics (in research contexts). Intranasal formulations like Melanotan 2 Nasal Spray 10mg may produce less nausea due to different pharmacokinetic profile, though this is anecdotal. Nausea typically attenuates with repeated dosing (tachyphylaxis), so initial doses produce the worst symptoms.

5. Is there a difference in effects between subcutaneous and intranasal administration?

Yes. Subcutaneous injection provides near-complete bioavailability (~95%), with peak plasma levels at 1–2 hours and half-life of 2–3 hours. Intranasal administration has lower bioavailability (20–40%), faster onset (15–30 minutes), and shorter half-life (~1 hour). For MC4R-mediated effects (erectile function), intranasal may produce faster onset but shorter duration. For MC1R-mediated pigmentation, subcutaneous is more efficient due to higher total exposure. No head-to-head human trial has compared routes directly. Arma Peptides supplies both lyophilised powder (for reconstitution and subcutaneous use) and Melanotan 2 Nasal Spray 10mg for intranasal administration, allowing researchers to select based on experimental design.

Conclusion: Evidence-Based Sourcing for UK Researchers

Melanotan 2 is among the most researched synthetic peptides in the melanocortin family, with published human trials confirming dose-dependent effects on pigmentation (MC1R-mediated) and erectile function (MC4R-mediated). The separation of these pathways—both pharmacologically and anatomically—is central to understanding how MT-2 works and why individual responses vary.

For UK-based researchers and informed consumers, sourcing quality comes down to verifiable purity (HPLC ≥99%), identity confirmation (mass spectrometry), transparent COAs, and proper cold-chain handling. The UK market includes suppliers across the quality spectrum, from pharmaceutical-grade to dangerously underdosed or contaminated material. Due diligence is non-negotiable.

Arma Peptides provides Melanotan 2 10mg UK with published COAs, UK-based shipping, and batch traceability. Additional formulations—including Melanotan 2 Acetate 10mg and Melanotan 2 Nasal Spray 10mg—are available for researchers requiring specific delivery routes or salt forms. All material is labelled for research use only, in compliance with UK regulations.

For related compounds with differential receptor selectivity, see PT-141 10mg UK (MC4R-selective, minimal pigmentation) or browse the full catalogue at Shop and Shop 2.

Disclaimer

This article is for informational and educational purposes only. Melanotan 2 is not approved for human use by the MHRA or any regulatory authority in the UK. It is supplied for research purposes only under UK law. Nothing in this article constitutes medical advice, and no claims are made regarding safety or efficacy for human consumption. All cited studies refer to investigational use in controlled research settings. Individuals considering use of melanotan 2 or related peptides do so entirely at their own risk and should consult qualified medical professionals and review all relevant literature. Arma Peptides does not condone or support use of research peptides outside of legitimate scientific research contexts.